Activin receptor type IIA ligands (ACVR2A ligands)

Activin receptor type IIA (ACVR2A) ligands are a group of signaling proteins within the Transforming Growth Factor-beta (TGF-beta) superfamily, primarily including Activin A, Activin B, Growth Differentiation Factor 8 (GDF8/Myostatin), and GDF11 (Source: UniProt P27037). These ligands function as extracellular signaling molecules that bind to the ACVR2A receptor to initiate the SMAD2/3 intracellular signaling pathway, which is essential for regulating erythropoiesis, bone homeostasis, and vascular cell proliferation (Source: Nature Reviews Drug Discovery, 2023). In diseases like pulmonary arterial hypertension (PAH), an imbalance in these ligands leads to pathological vascular remodeling and increased pulmonary arterial pressure (Source: NEJM, 2024, DOI: 10.1056/NEJMoa2314554). Therapeutic targeting of these ligands is achieved through ligand traps, such as Sotatercept, which is a fusion protein comprising the extracellular domain of ACVR2A and a human IgG1 Fc domain (Source: FDA, Winrevair Label). By sequestering circulating ligands, these drugs prevent receptor activation and restore signaling equilibrium, leading to improved clinical outcomes in PAH and certain hematological disorders. This approach represents a shift from traditional vasodilators to disease-modifying therapies that address the underlying structural changes in the vasculature.

Other names

TGF-beta superfamily ligandsActivinsGrowth differentiation factorsGDFsMyostatinBone morphogenetic proteins

Ligand sequestration (ligand trap) to prevent binding to the Activin receptor type IIA and subsequent SMAD2/3 signaling.